Chief Executive Officer
Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he was consultant at McKinsey & Company and engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Masters degree in Applied Physics from the University of Delft, The Netherlands, and an MBA from INSEAD, France.
Chief Financial Officer
Robbert van Heekeren is Chief Financial Officer of Kiadis Pharma. Before joining Kiadis Pharma he was Executive Director, Head Global Finance & Control at Organon, the former pharmaceutical business unit of AkzoNobel. Mr. Van Heekeren worked for Organon for more than 10 years in various international management positions. Mr. van Heekeren holds a Masters degree in Economics from Tilburg University, The Netherlands, and a Masters degree in Industrial Engineering & Management Science from Eindhoven University of Technology, The Netherlands.
Chief Operations Officer
Jan Feijen is Chief Operations Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Vice President Manufacturing and Technical Operations, Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held various executive positions at Crucell, Avebe and Gist Brocades. Mr. Feijen holds a Masters degree in Applied Physics from the University of Delft, The Netherlands.
Chief Medical Officer
Andrew Sandler is the Chief Medical Officer at Kiadis Pharma. Prior to joining the company, he was Senior Vice President, Medical Affairs, at Medivation (now part of Pfizer). Prior to that he was CMO at Dendreon Pharmaceuticals and Spectrum Pharma. He has also held senior-level positions with several other leading biotechnology and pharmaceutical companies, including Bayer Healthcare, Berlex and Seattle Genetics. Dr. Sandler obtained his MD from Mount Sinai School of Medicine, New York and completed a fellowship in medical oncology at University of California San Francisco. A US citizen, Dr. Sandler is a board certified medical oncologist and has treated many patients with hematologic malignancies, including bone marrow transplant patients.
Head of IR and Communications
Karl Hård is the Head of IR and Communications. Before joining our team, he has spent almost 20 years at AstraZeneca PLC based in Sweden and the UK. Over a period of 10 years, he held senior roles within Investor Relations, latterly as head of IR. Prior to that, he worked as Global Program Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. Karl’s scientific experience covers numerous fields, including oncology and immunology, as evidenced by over 40 published scientific articles in peer-reviewed international journals.
General Counsel & Corporate Secretary
Margot Hoppe is General Counsel & Corporate Secretary. She has over 20 years of experience in corporate legal affairs and worked for various biotechnology companies including Gist-Brocades and DSM. Ms. Hoppe has Masters degrees in Law and Political Science from the Erasmus University of Rotterdam, The Netherlands.